癌化学预防药维胺酸的药理学研究  

Pharmacological Studies of N-4-(hydroxycarbophenyl) Retinamide

作　　者：韩锐[1] 焦鹭 路莹 顾企民 刘红岩[1] 夏丽娟[1] 杜丛之 

机构地区：[1]中国医学科学院药物研究所

出　　处：《中国医学科学院学报》1991年第2期101-107,共7页Acta Academiae Medicinae Sinicae

摘　　要：维胺酸(N-4-(hydroxycarbophenyl)-retinamide;RⅡ)在30～50mg/kg的剂量下对大鼠移植性软骨肉瘤有明显治疗作用。 低浓度的RⅡ对HL-60细胞有较弱的分化诱导活性,同时加入S86019可使其活性增强。流式细胞光度术分析表明,RⅡ可使HL-60细胞产生G_1期阻断,与S86019联合应用有良好协同阻断效应,使90％细胞积聚在G_1期,Northern blot分析表明,用RⅡ和S86019联合处理HL-60细胞12h后,c-myc表达明显受到抑制,与DNA合成密切相关的胸腺嘧啶核苷酸合成酶mRNA表达也受到抑制。Our studies show that the growth of transplantable chondrosarcoma in rats is inhibited significantly , by N-4-(hydroxycarbophenyl) retinamide (RII) at a dosage of 50mg/kg. RII show a weak ability to induce the differentiation of HL-60 cells at a concentration of 1 umol/L.However, most of the HL-60 cells were induced to differentiate along granulocyte lineage after exposure to RII (1μmol/L) and S86019 (10μg/ml). Flow cytometry studies indicated that the majority of HL-60 cells were arrested in G1 phase by RII plus S86019.Northern blot analysis clearly demonstrated that c-myc expression was inhibited after treating HL-60 cells with RII plus S86019 for 12 hours. Moreover, thymidylate synthetase mRNA transcription was inhibited in those differentiated cells.

关 键 词：维胺酸 分化 癌基因C-MYC 诱导 

分 类 号：R979.1[医药卫生—药品]